Last reviewed · How we verify
aprotinin or tranexamic acid
Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, thereby reducing fibrinolysis and preventing excessive bleeding.
Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, thereby reducing fibrinolysis and preventing excessive bleeding. Used for Surgical bleeding, Menorrhagia.
At a glance
| Generic name | aprotinin or tranexamic acid |
|---|---|
| Sponsor | German Heart Center |
| Drug class | Antifibrinolytic |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Tranexamic acid is a synthetic derivative of the amino acid lysine. It binds to plasminogen and prevents its activation to plasmin, which is the primary enzyme responsible for fibrinolysis. By inhibiting fibrinolysis, tranexamic acid reduces the breakdown of blood clots and prevents excessive bleeding.
Approved indications
- Surgical bleeding
- Menorrhagia
Common side effects
- Nausea
- Vomiting
- Headache
- Dizziness
- Hypertension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aprotinin or tranexamic acid CI brief — competitive landscape report
- aprotinin or tranexamic acid updates RSS · CI watch RSS
- German Heart Center portfolio CI